Erasca Form 144 Filed on April 1, 2026 Form 144 filed for Erasca on Apr 1, 2026; Rule 144 requires filing for sales >5,000 shares or $50,000 and limits affiliates to 1% of outstanding shares or 4-week avg vol.

Erasca Form 144 Filed on April 1, 2026: Form 144 filed for Erasca on Apr 1, 2026; Rule 144 requires filing for sales >5,000 shares or $50,000 and limits affiliates to 1% of outstanding shares or 4-week avg vol. 👈 Read full analysis #Erasca #Form144 #SECRules #StockMarket #Investment

Erasca Gains IND Clearance for Two RAS-Targeting Cancer Therapies FDA clears ERAS-4001 and ERAS-0015 to begin clinical testing ahead of schedule Erasca, Inc. (Nasdaq: ERAS) announced that the U.S. Food and Drug Administrati

#ERAS Inc. secures FDA IND clearance for two novel RAS-targeting cancer therapies, advancing its mission to erase cancer!
Precision oncology is moving forward — fast.
#Erasca #CancerResearch #Oncology #RAS #FDA #BiotechNews
Read more: prismmarketview.com/erasca-gains...

🚨 #JPM21 news starting: @JLimMD’s #ERASCA unveils #SHP2 & #MAPK signaling strategy. Reminds me of @jaybradner’s tweet below.



@PatelOncology @VincentRK @MilkaKostic @DFCI_ChemBio #molecularglues @adamfeuerstein @JohnCendpts @LifeSciVC @HartungIngo